Evidence map›Paper›PMID 32362972›Full record

ArticleJournal of clinical medicine research2020

Cannabis Use in Inpatients With Schizophrenia Spectrum Disorders at a Community Hospital.

Olaniyi Olayinka, Chiedozie Ojimba, Brook Alemu, Olalekan Olaolu, Desta Edomias, Olusegun Popoola, Jisha Kallikkadan, Terence Tumenta, Vijay Gayam, Leon Valbrun and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical medicine research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Prevalence of cannabis use in people with psychosis in KwaZulu-Natal, South Africa.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2022
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Olaniyi OlayinkaDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Chiedozie OjimbaDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Brook AlemuIntegrated Health Sciences Program, School of Health Sciences, Western Carolina University, Cullowhee, NC, USA.
Olalekan OlaoluDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Desta EdomiasDepartment of Internal Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Olusegun PopoolaDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Jisha KallikkadanDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Terence TumentaDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Vijay GayamDepartment of Internal Medicine, Interfaith Medical Center, Brooklyn, NY, USA.
Leon ValbrunDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Tolu OluponaDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Jason HershbergerDepartment of Psychiatry and Behavioral Sciences, Interfaith Medical Center, Brooklyn, NY, USA.
Interfaith Medical Center · USWestern Carolina University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCannabis is the second most used recreational drug in the United States and one of the most used substances in patients with schizophrenia spectrum disorder (SSD). Unfortunately, the increased use is likely to continue as more states legalize recreational use of cannabis. Although the association between cannabis and schizophrenia has been studied extensively, the understanding of the relationship is still evolving. In this study, we sought to determine the prevalence and potential factors associated with cannabis use (CU) among inpatients with SSD at a community teaching hospital.

methodsWe performed a retrospective review of the electronic medical charts of patients discharged from the psychiatric unit of our hospital from July 1, 2017 through October 31, 2017. Patients were included in this study if: 1) They were ≥ 18 years old; 2) They had discharge diagnosis of SSD; and 3) They had urine drug testing performed. Pertinent sociodemographic and clinical variables, including substance use status and hospital length of stay (LOS), were abstracted. Univariate frequencies and summary statistics were performed. Odds ratios (ORs) were determined by logistic regression analysis of bivariate and multivariate analyses.

resultsThree hundred sixty-five (52.2%) patients had a discharge diagnosis of SSD, and only 322 had urine toxicology result for cannabinoids and were included in analysis. Of the 322 patients, 41.5% (n = 133) screened positive for cannabinoids. Of the 133 patients, 78% were African American, 15% were Hispanic and 5% were White; 77% were male and the median age was 36 years. Bivariate analyses showed tobacco use (OR: 2.8, 95% confidence interval (CI): 1.7 - 4.6), alcohol use (OR: 3.4, 95% CI: 2.9 - 7.0), younger age (OR: 2.8, 95% CI: 1.8 - 4.5), male gender (OR: 2.9, 95% CI: 2.2 - 3.2), unemployment (OR: 3.91, 95% CI: 3.49 - 7.35), homelessness (OR: 3.18, 95% CI: 2.76 - 3.84) and LOS (OR: 3.46, 95% CI: 2.93 - 4.31) were significantly associated with CU. Result of multivariate analysis was similar to that found in bivariate analysis.

conclusionsCU appears to be prevalent among patients with SSD. Clinicians and public health professionals are encouraged to understand the health implications of its use in patients with mental illness especially against the backdrop of current marijuana laws.

Indexed as

CannabisMarijuanaPublic healthSchizophreniaSchizophrenia spectrum disordersSubstance use disorder

Identifiers

PMID32362972
PMCPMC7188370
OpenAlexW3015228406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.